GALLBLADDER CANCER
TREATMENT
A highly aggressive biliary tract cancer with improving molecular targeting. Chinese surgical volume and cost-accessible standard therapy create specific advantages for South and Southeast Asian patients.
analyticsAt a Glance
- check_circleGallbladder cancer is often diagnosed at an advanced stage when surgery is no longer possible
- check_circleFGFR2 and ERBB2 alterations are present in a subset and can be targeted with approved drugs
- check_circleGemcitabine plus cisplatin or capecitabine is standard first-line systemic therapy
- check_circleClinical trials and specialist biliary oncology centres offer the best outcomes in advanced disease
What This Means for Patients
Gallbladder cancer treatment follows the biliary tract cancer algorithm with specific molecular differences. HER2 amplification is more common (~10โ20%) than in intrahepatic cholangiocarcinoma. FGFR2 fusions are rare. MSI-H occurs in ~5%. These differences mean HER2 testing is prioritised over FGFR testing for gallbladder cancer patients.
First-Line: Chemo Plus Checkpoint
Gemcitabine/cisplatin plus durvalumab (TOPAZ-1) or pembrolizumab (KEYNOTE-966) is the first-line standard. Chinese domestic PD-1 inhibitors (sintilimab, tislelizumab) offer substantially lower cost access.
HER2-Directed Therapy
HER2 amplification in 10โ20% opens targeted therapy options. Trastuzumab, T-DXd, and disitamab vedotin (RC48, Chinese-developed HER2 ADC) have activity. HER2 IHC and FISH testing is essential for all gallbladder cancer patients.
Surgical Treatment: Radical Cholecystectomy
Early-stage gallbladder cancer (T1bโT3) is treated with radical cholecystectomy including liver bed resection (segments IVb and V), regional lymphadenectomy, and port-site excision. If cancer is suspected pre-operatively, laparoscopic cholecystectomy should not be performed due to bile spillage and peritoneal seeding risk. Chinese academic centres (FUSCC, CAMS) perform this at high volume.
Additional Treatment Options
FOLFOX Second-Line
Standard second-line after gemcitabine/cisplatin failure (ABC-06 trial). For HER2-amplified patients, targeted therapy is preferred over FOLFOX at second line.
MSI-H Gallbladder Cancer
MSI-H gallbladder cancer (~5%) responds to checkpoint immunotherapy. MSI testing on all patients is recommended to identify this responsive subset.
Peritoneal Disease and HIPEC
Peritoneal metastases are common. Intraperitoneal chemotherapy including HIPEC is being explored at Chinese academic programmes for selected patients with limited peritoneal spread.
Benefits and Limitations
Benefits
- Cost-accessible first-line checkpoint-chemotherapy combination
- HER2-directed therapy access for amplified cases
- High-volume hepatobiliary surgical expertise for resectable disease
- Geographically and financially accessible for South/Southeast Asian patients
Limitations
- Advanced gallbladder cancer has median OS ~11โ12 months with best treatment
- Molecular targeting advances meaningful but not transformative for this cancer type
- 70โ80% of patients present with unresectable or metastatic disease
When to Consider This Option
Cost-Accessible Standard Treatment
Advanced gallbladder cancer needs first-line checkpoint-chemotherapy at affordable cost.
HER2 Amplification Confirmed
HER2-directed therapy access through Chinese commercial or trial pathway.
Resectable Disease
Specialist hepatobiliary surgical evaluation at a high-volume centre.
Related Rare Cancer Guides
Explore more from the Rare Cancer Treatments series.
Frequently Asked Questions
About Gallbladder Cancer
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Evaluating Gallbladder Cancer Treatment Options?
CancerFax connects gallbladder cancer patients with specialist hepatobiliary surgery, HER2-directed therapy access, and cost-accessible standard treatment at Chinese academic centres.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.